新冠病毒肺炎：一场正在展现的血管噩梦。
COVID-19: a vascular nightmare unfolding.
作者信息
Yin Qinan, Huang Youjin, Wang Hulin, Wang Yin, Huang Xuefei, Song Yujie, Wang Yueyuan, Han Lizhu, Yuan Bian
机构信息
Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Department of Vascular Surgery Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
出版信息
Front Immunol. 2025 Aug 1;16:1593885. doi: 10.3389/fimmu.2025.1593885. eCollection 2025.
The emergence of COVID-19 has been associated with an increased risk of arteriovenous thrombosis, with immune inflammation playing a significant role in the pathogenesis of thrombosis. Numerous drug-related clinical trials have been undertaken to prevent thrombosis, and guidelines for its prevention and treatment are continuously evolving as our understanding of the disease progresses. This article provides a comprehensive review of the mechanisms underlying thrombosis in COVID-19 patients, as well as the advancements in clinical trials and guidelines for thrombosis prevention with pharmacological interventions.
新型冠状病毒肺炎（COVID-19）的出现与动静脉血栓形成风险增加有关，免疫炎症在血栓形成的发病机制中起重要作用。为预防血栓形成已开展了大量与药物相关的临床试验，随着我们对该疾病认识的进展，其预防和治疗指南也在不断演变。本文全面综述了COVID-19患者血栓形成的潜在机制，以及药物干预预防血栓形成的临床试验进展和指南。
Zotero 插件